Completed PHASE3 INTERVENTIONAL NCT00519558

Growth Hormone Deficiency in Adults (GHDA)

Investigation of the Efficacy and Safety of NN-220 for 24 Weeks in Adults With Growth Hormone Deficiency

Sponsor: Novo Nordisk A/S

Conditions Adult Growth Hormone Deficiency Growth Hormone Disorder

Interventions somatropin

Updated 6 times since 2017 Last updated: Feb 27, 2017 Started: May 31, 2003 Primary completion: Jan 24, 2005 Completion: Jan 24, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Adult Growth Hormone Deficiency and Growth Hormone Disorder and is currently completed. Novo Nordisk A/S leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Mar 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Mar 2017 [monthly]

Completed PHASE3

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan